Lyka Labs Ltd. (NSE: LYKALABS, BSE: 500259) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹294 Cr, it ranks #2,346 by market cap among the 6,197 Indian listed companies on FinBizNet, and #54 of 86 in Medicinal Chemicals and Botanical Products. At ₹84.62 (as of 16 Nov 2026), the share price is 5.3% below its 52-week high of ₹89.40 and 91.9% above its 52-week low of ₹44.10. The share price is down 9.6% over one year and up 24.4% over three months.
| Current Price | ₹84.62 |
|---|---|
| Market Cap | ₹294 Cr |
| NSE Symbol | LYKALABS |
| BSE Code | 500259 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -10.74% |
| Return on Assets | -4.25% |
| 52-Week Range | ₹44.10 – ₹89.40 |
| 1-Year Price Change | -9.6% |
| 3-Month Price Change | +24.4% |
| Beta (1Y) | 0.1 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.lykalabs.com |
| Revenue | ₹44 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 2.9% |
| EPS (Basic) | ₹0.36 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Lyka Labs Ltd. reported revenue of ₹44 Cr in Q2 FY27, up 20.6% from ₹37 Cr in Q2 FY26 and up 4.5% from ₹42 Cr in Q1 FY27. It posted a net profit of ₹1 Cr for the quarter, against a net loss of ₹3 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹28 Cr (Q4 FY26) to ₹44 Cr (Q2 FY27). The company reported a net loss in 3 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹44 Cr | ₹1 Cr | 2.9% |
| Q1 FY27 | ₹42 Cr | ₹2 Cr | 4.8% |
| Q4 FY26 | ₹28 Cr | −₹8 Cr | −28.8% |
| Q3 FY26 | ₹31 Cr | −₹0 Cr | −0.5% |
| Q2 FY26 | ₹37 Cr | −₹3 Cr | −8.8% |
| Q1 FY26 | ₹33 Cr | ₹1 Cr | 3.0% |
| Q4 FY25 | ₹33 Cr | ₹2 Cr | 6.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 58.45% of Lyka Labs Ltd.'s shares as of Sept 2026, against 58.16% in Sept 2025 (+0.29 percentage points).
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, anti-fungal and bacterial, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports it
1. Pharmaceuticals-This segment provides pharmaceutical products and pharma related services.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Lyka Labs Ltd. | ₹294 Cr | n/m | -10.74% | ₹44 Cr | -9.6% |
Listed by market capitalisation. Ratios are shown for context only.
Lyka Labs Ltd. is trading at ₹84.62, with a market capitalisation of ₹294 Cr.
Lyka Labs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Lyka Labs Ltd. has a return on equity of -10.74%.
Lyka Labs Ltd. is listed on the NSE under the symbol LYKALABS and on the BSE under the scrip code 500259.
Lyka Labs Ltd.'s share price is down 9.6% over one year and up 24.4% over three months. Its 52-week range is ₹44.10 to ₹89.40.
In Q2 FY27, Lyka Labs Ltd. reported revenue of ₹44 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.36 (consolidated, parsed from the company's exchange filing).
Lyka Labs Ltd. reported revenue of ₹44 Cr in Q2 FY27, up 20.6% from ₹37 Cr in Q2 FY26 and up 4.5% from ₹42 Cr in Q1 FY27.
Promoters held 58.45% of Lyka Labs Ltd.'s shares as of Sept 2026, against 58.16% in Sept 2025 (+0.29 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.